GraySpace Therapeutics

03/08/2024

Excited to be in Lisbon at presenting brand new MRI and MS imaging data on a novel inducible plasmalogen deficient and plasmalogen precursor PPI-1011. Med-Life Discoveries

09/21/2021

We felt there was no better day than today, World Alzheimer’s Day, to release our latest video animation highlighting one of the central mechanisms of action by which our compounds are anticipated to improve memory and cognition. Enjoy!

For more information visit: https://grayspacetherapeutics.com/news/world-alzheimers-day-2021

12/01/2020

Newly published research provides strong support for the link between plasmalogens and Alzheimer's disease!

Check out our link below for more information on the paper and how we believe it strengthens our programs.

grayspacetherapeutics.com/news/new-support-for-the-link-between-plasmalogens-and-alzheimers

Earlier this month a new paper published in Nature Communications entitled “Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer’s disease” provided strong support for the association between plasma plasmalogen levels and Alzheimer’s disease. Analyzing the pla...

10/30/2020

GraySpace will be attending the Neuroscience Virtual Partnering event this November. For more information click the link below.

grayspacetherapeutics.com/news/0xertw11q7u6rlju9qj8zblnoqiabv

GraySpace Thereapeutics’ COO, Dr. Shawn Ritchie, will be attending the Neuroscience Virtual Partnering event this November. This event brings together leading researchers, biotech, and biopharma companies for four days of networking and partnering. If you are attending the event and are interested...

10/28/2020

GraySpace is thrilled to have the opportunity to present at tomorrow's Landmark Virtual Forum, put on by the Landmark Angels Group. We will be discussing our revolutionary new approach to treating what we believe is the underlying metabolic cause of Alzheimer's disease.

10/23/2020

In support of our Alzheimer's drug development program, GraySpace Therapeutics will be attending the 13th Clinical Trials in Alzheimer's Disease conference.

https://grayspacetherapeutics.com/news/pib4l4u5hpur1fl7rub8yxycgz3pbp-ftn7l

GraySpace Therapeutics is excited to be attending the 13th Clinical Trials on Alzheimer’s Disease 2020 (CTAD2020). This conference brings together the world’s experts on the treatment of AD for four days of presentations on the latest updates on clinical trial results and best practices. This in...

10/11/2020

We would love to meet you (virtually) at BioEurope later this month. We are developing a therapeutic to address an underlying metabolic deficiency increasingly believed to drive Alzheimer’s disease pathology.

https://grayspacetherapeutics.com/news/pib4l4u5hpur1fl7rub8yxycgz3pbp

GraySpace Therapeutics’ COO, CFO and CSO will be attending Bio Europe Digital October 26-29th. We are looking forward to talking to companies or firms that are interested in investing in a revolutionary new therapeutics approach to the treatment of Alzheimer’s and Parkinson’s disease. If you w...

09/21/2020

At GraySpace Therapeutics, we are seeking to develop a fundamentally new approach for the treatment of Alzheimer’s disease. For more information, visit our site below.

https://grayspacetherapeutics.com/science

One Day . . .All we’ll forget, is what Alzheimer’s was. The Plasmalogen Deficiency Hypothesis   Plasmalogen deficiency has long been associated with dementia, and is now known to be a key underlying factor in the development and progression of dementias including Alzheimer’s disease. While pl...

09/21/2020

More than 5 million Americans are living with Alzheimer's disease and this is expected to reach ~14 million by 2050. In addition to the physical stress and emotional toll of the disease, the national cost of caring for people with dementia will be $305 billion this year.

09/21/2020

Today is World Alzheimer’s Day and this year’s theme is: “Let’s talk about dementia.” Although globally over 50 million people are living with dementia, 2 out of 3 people believe there is little understanding of dementia in their countries and this year’s theme expresses the urgency needed to change this. For more information on Alzheimer’s disease and dementia visit https://www.alz.org/.

09/15/2020

GraySpace is grateful for the opportunity to pitch in the Start-up Forum at the ADDF's 21st International Conference on Alzheimer's Drug Discovery.

https://grayspacetherapeutics.com/news/grayspace-invited-to-present-at-addf-conference

GraySpace Therapeutics has been invited to present at the Start-up Forum at the 21st International Conference on Alzheimer’s Drug Discovery, put on by the Alzheimer’s Drug Discovery Foundation (ADDF). GraySpace will be one of six companies who will pitch their company in a short presentation on ...

08/21/2020

We would love to meet you (virtually) at BioPharm America and tell you about our approach to the treatment of Alzheimer's and Parkinson's.

grayspacetherapeutics.com/news/2wnzm9r05s8ba1al1lcw8f5qhqcpbs

GraySpace Therapeutics will be attending the virtual partnering event BioPharm America taking place from Septemeber 21-24th, 2020. Our goal is to meet (virtually) with companies or firms interested in investing in a fundamentally new approach to the treatment of Alzheimer’s and Parkinson’s. Anyo...

07/14/2020

GraySpace is excited to announce that their parent company, Med-Life Discoveries, was awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research, which will support GraySpace’s Parkinson’s therapeutic program.

https://grayspacetherapeutics.com/news/qidq404g9j2c86zewzuwp38mjiwpnl

GraySpace Therapeutics’ parent company Med-Life Discoveries (MLD) has recently been awarded a “Spring 2020 Use of Parkinson’s Disease Biosamples” grant from The Michael J Fox Foundation for Parkinson’s Research (MJFF). “This grant will provide a deeper look into the role of plasmalogens ...

07/13/2020

GraySpace Therapeutics has officially begun the process of developing a fully certified GLP-lab in Saskatoon. For full details see the link below.

https://grayspacetherapeutics.com/news/veh7ed7at3jmich16cb45wtbwrvgum

GraySpace is pleased to announce that in partnership with Med-Life Discoveries (MLD), it has acquired full access to new laboratory space at Innovation Place in Saskatoon. The space will house several analytical instrumentation platforms, but more importantly, will be undergoing GLP (Good Laboratory

07/06/2020

GraySpace Therapeutics is lead by a world-class team of senior pharmaceutical executives and leading plasmalogen research scientists. Meet the team below.

https://grayspacetherapeutics.com/about

07/06/2020

It's official, we're incorporated! GraySpace Therapeutics Inc was created out of a partnership between Med-Life Discoveries and Induran Ventures as a pharmaceutical company fully dedicated to advancing plasmalogen-based drugs for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's.

https://grayspacetherapeutics.com/news/blog-post-title-one-6wswz

Med-Life Discoveries is pleased to announce a partnership with Induran Ventures (Toronto, Canada) that has resulted in the creation of GraySpace Therapeutics Inc. GraySpace is a US incorporated pharmaceutical company fully dedicated to the therapeutic development of plasmalogen-based drugs for demen

07/06/2020

Interested in supporting a completely new approach to the treatment of neurogenerative disorders?

Visit the link below and help us change the future for patients with Alzheimer's and Parkinson's.

https://grayspacetherapeutics.com/for-investors